Diabetes is an independent predictor of survival 17 years after myocardial infarction: Follow-up of the TRACE registry

Cardiovascular Diabetology

Volumn 9, Issue , 2010, Pages

  Kümler, Thomas ^a   Gislason, Gunnar H ^b   Køber, Lars ^a   Torp Pedersen, Christian ^b  

^a Rigshospitalet   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; TRANDOLAPRIL;

AGED; ARTICLE; DEATH; DIABETES MELLITUS; DISEASE COURSE; FEMALE; FOLLOW UP; HAZARD RATIO; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; PREDICTOR VARIABLE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; REGISTER; SURVIVAL; DENMARK; HOSPITALIZATION; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SURVIVOR; TIME;

AGED; DENMARK; DIABETES MELLITUS; FEMALE; HOSPITALIZATION; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MULTICENTER STUDIES AS TOPIC; MYOCARDIAL INFARCTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVORS; TIME FACTORS;

EID: 77952845847     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-9-22     Document Type: Article

References (31)

1. Bartnik M, Malmberg K, Hamsten A, Efendic S, Norhammar A, Silveira A, Tenerz A, Ohrvik J, Ryden L. Abnormal glucose tolerance--a common risk factor in patients with acute myocardial infarction in comparison with population-based controls. J Intern Med 2004, 256(4):288-297. 10.1111/j.1365-2796.2004.01371.x, 15367171.
2. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002, 359(9324):2140-2144. 10.1016/S0140-6736(02)09089-X, 12090978.
3. Janszky I, Hallqvist J, Ljung R, Ahlbom A, Hammar N. Prognostic role of the glucometabolic status assessed in a metabolically stable phase after a first acute myocardial infarction: the SHEEP study. J Intern Med 2008,
4. Melchior T, Kober L, Madsen CR, Seibaek M, Jensen GV, Hildebrandt P, Torp-Pedersen C. Accelerating impact of diabetes mellitus on mortality in the years following an acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. European heart journal 1999, 20(13):973-978. 10.1053/euhj.1999.1530, 10361050.
5. Schramm TK, Gislason GH, Kober L, Rasmussen S, Rasmussen JN, Abildstrom SZ, Hansen ML, Folke F, Buch P, Madsen M, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008, 117(15):1945-1954. 10.1161/CIRCULATIONAHA.107.720847, 18378618.
6. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998, 21(9):1414-1431. 10.2337/diacare.21.9.1414, 9727886.
7. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. European heart journal 2008, 29(23):2909-2945. 10.1093/eurheartj/ehn416, 19004841.
8. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995, 333(25):1670-1676. 10.1056/NEJM199512213332503, 7477219.
9. The TRAndolapril Cardiac Evaluation (TRACE) study: rationale, design, and baseline characteristics of the screened population. The Trace Study Group. Am J Cardiol 1994, 76(10):44C-50C.
10. Kober L, Torp-Pedersen C, Carlsen J, Videbaek R, Egeblad H. An echocardiographic method for selecting high risk patients shortly after acute myocardial infarction, for inclusion in multi-centre studies (as used in the TRACE study). TRAndolapril Cardiac Evaluation. European heart journal 1994, 15(12):1616-1620.
11. Mak KH, Moliterno DJ, Granger CB, Miller DP, White HD, Wilcox RG, Califf RM, Topol EJ. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1997, 30(1):171-179. 10.1016/S0735-1097(97)00118-6, 9207639.
12. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999, 354(9179):617-621. 10.1016/S0140-6736(98)12131-1, 10466661.
13. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999, 22(2):233-240. 10.2337/diacare.22.2.233, 10333939.
14. Norhammar AM, Ryden L, Malmberg K. Admission plasma glucose. Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients. Diabetes Care 1999, 22(11):1827-1831. 10.2337/diacare.22.11.1827, 10546015.
15. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000, 355(9206):773-778. 10.1016/S0140-6736(99)08415-9, 10711923.
16. Granger CB, Califf RM, Young S, Candela R, Samaha J, Worley S, Kereiakes DJ, Topol EJ. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol 1993, 21(4):920-925. 10.1016/0735-1097(93)90348-5, 8450161.
17. Waller BF, Palumbo PJ, Lie JT, Roberts WC. Status of the coronary arteries at necropsy in diabetes mellitus with onset after age 30 years. Analysis of 229 diabetic patients with and without clinical evidence of coronary heart disease and comparison to 183 control subjects. Am J Med 1980, 69(4):498-506. 10.1016/S0149-2918(05)80002-5, 7424939.
18. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, Wedel H, Welin L. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995, 26(1):57-65. 10.1016/0735-1097(95)00126-K, 7797776.
19. Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K, Efendic S, Fisher M, Hamsten A, Herlitz J, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. European heart journal 2005, 26(7):650-661. 10.1093/eurheartj/ehi199, 15728645.
20. Cheung NW, Wong VW, McLean M. The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care 2006, 29(4):765-770. 10.2337/diacare.29.04.06.dc05-1894, 16567812.
21. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004, 141(6):421-431.
22. Stettler C, Allemann S, Juni P, Cull CA, Holman RR, Egger M, Krahenbuhl S, Diem P. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J 2006, 152(1):27-38. 10.1016/j.ahj.2005.09.015, 16824829.
23. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352(9131):854-865. 10.1016/S0140-6736(98)07037-8, 9742977.
24. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352(9131):837-853. 10.1016/S0140-6736(98)07019-6, 9742976.
25. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360(2):129-139. 10.1056/NEJMoa0808431, 19092145.
26. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358(24):2545-2559. 10.1056/NEJMoa0802743, 18539917.
27. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358(24):2560-2572. 10.1056/NEJMoa0802987, 18539916.
28. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999, 353(9153):617-622. 10.1016/S0140-6736(98)07368-1, 10030326.
29. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009, 119(2):351-357. 10.1161/CIRCULATIONAHA.108.191305, 19095622.
30. Executive summary: standards of medical care in diabetes--2009. Diabetes Care 2009, 32(Suppl 1):S6-12. 2613586, 19118288.
31. Botkin NF, Spencer FA, Goldberg RJ, Lessard D, Yarzebski J, Gore JM. Changing trends in the long-term prognosis of patients with acute myocardial infarction: a population-based perspective. Am Heart J 2006, 151(1):199-205. 10.1016/j.ahj.2005.03.016, 16368319.